These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
835 related articles for article (PubMed ID: 26046399)
21. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review. Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997 [TBL] [Abstract][Full Text] [Related]
22. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Sarkaria JN; Hu LS; Parney IF; Pafundi DH; Brinkmann DH; Laack NN; Giannini C; Burns TC; Kizilbash SH; Laramy JK; Swanson KR; Kaufmann TJ; Brown PD; Agar NYR; Galanis E; Buckner JC; Elmquist WF Neuro Oncol; 2018 Jan; 20(2):184-191. PubMed ID: 29016900 [TBL] [Abstract][Full Text] [Related]
23. Gallego L; Ceña V Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861 [TBL] [Abstract][Full Text] [Related]
24. The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. Fan HC; Chi CS; Chang YK; Tung MC; Lin SZ; Harn HJ Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385679 [TBL] [Abstract][Full Text] [Related]
25. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment Yang J; Shi Z; Liu R; Wu Y; Zhang X Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864 [TBL] [Abstract][Full Text] [Related]
26. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier. Wadhwa K; Chauhan P; Kumar S; Pahwa R; Verma R; Goyal R; Singh G; Sharma A; Rao N; Kaushik D Oncol Res; 2024; 32(5):877-897. PubMed ID: 38686045 [TBL] [Abstract][Full Text] [Related]
27. New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it. Peschillo S; Caporlingua A; Diana F; Caporlingua F; Delfini R J Neurointerv Surg; 2016 Oct; 8(10):1078-82. PubMed ID: 26541791 [TBL] [Abstract][Full Text] [Related]
28. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598 [TBL] [Abstract][Full Text] [Related]
29. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209 [TBL] [Abstract][Full Text] [Related]
30. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012 [TBL] [Abstract][Full Text] [Related]
31. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy. Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807 [TBL] [Abstract][Full Text] [Related]
33. Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier. Lim SH; Yee GT; Khang D Int J Nanomedicine; 2024; 19():2529-2552. PubMed ID: 38505170 [TBL] [Abstract][Full Text] [Related]
34. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous. Drapeau A; Fortin D Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730 [TBL] [Abstract][Full Text] [Related]
35. Current Challenges and Opportunities in Treating Glioblastoma. Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750 [TBL] [Abstract][Full Text] [Related]
36. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607 [TBL] [Abstract][Full Text] [Related]
37. Design of new protein drug delivery system (PDDS) with photoactive compounds as a potential application in the treatment of glioblastoma brain cancer. de Melo MT; Piva HL; Tedesco AC Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110638. PubMed ID: 32204072 [TBL] [Abstract][Full Text] [Related]
38. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186 [TBL] [Abstract][Full Text] [Related]
39. Current Development of Glioblastoma Therapeutic Agents. Wang Z; Peet NP; Zhang P; Jiang Y; Rong L Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531 [TBL] [Abstract][Full Text] [Related]